Novobismol tablets 120mg, No. 56

peptic ulcer of the stomach and duodenum in the acute phase, incl. associated with Helicobacter pylori;

chronic gastritis and gastroduodenitis in the acute phase, incl. associated with Helicobacter pylori;

functional dyspepsia, not associated with organic diseases of the gastrointestinal tract;

irritable bowel syndrome, occurring mainly with symptoms of diarrhea.

Inside, 30 minutes before meals.

Adults and children over 12 years old - 1 tab. 3 times a day and 1 table. at night or 2 tables. 2 times a day.

Children from 8 to 12 years old - 1 table. 2 times a day.

Children from 4 to 8 years old - at a dose of 8 mg / kg / day; the daily dose is divided into 2 doses.

The tablets should be taken with a little water. The duration of the course of treatment is 4Ц8 weeks. For the next 8 weeks, do not use drugs containing bismuth. For the eradication of Helicobacter pylori, it is advisable to use bismuth tripotassium dicitrate in combination with other antibacterial agents with anti-Helicobacter activity.

The drug should not be used for more than 8 weeks. It is not recommended to exceed the established daily doses for adults and children during treatment with NovobismolЃ.

During the treatment period, you should not use other preparations containing bismuth.

At the end of the course of treatment with the drug in the recommended doses, the concentration of the active active substance in the blood plasma does not exceed 3-5.8 mcg / l, and intoxication is observed only at a concentration above 100 mcg / l.

When using NovobismolЃ, stool may turn dark due to the formation of bismuth sulfide. Sometimes there is a slight darkening of the tongue.

individual intolerance to the drug;

severe renal dysfunction;

pregnancy;

lactation period;

children under 4 years of age.

pharmachologic effect

Antiulcer agent with bactericidal activity against Helicobacter pylori. It also has anti-inflammatory and astringent properties. In the acidic environment of the stomach, insoluble bismuth oxychloride and citrate are precipitated, chelated compounds are formed with a protein substrate in the form of a protective film on the surface of ulcers and erosions. By increasing the synthesis of prostaglandin E, the formation of mucus and the secretion of bicarbonate, it stimulates the activity of cytoprotective mechanisms, increases the resistance of the gastrointestinal mucosa to the effects of pepsin, hydrochloric acid, enzymes and bile salts. Leads to the accumulation of epidermal growth factor in the defect area. Reduces the activity of pepsin and pepsinogen.

Pharmacokinetics

Practically not absorbed from the gastrointestinal tract. It is excreted mainly in the feces. A small amount of bismuth entering the plasma is excreted from the body by the kidneys. Side effect From the digestive system: nausea, vomiting, more frequent bowel movements, constipation are possible. These phenomena are not dangerous to health and are temporary. Allergic reactions: skin rash, itching of the skin. With prolonged use in high doses - encephalopathy associated with the accumulation of bismuth in the central nervous system. If any of the side effects indicated in the instructions are aggravated or any other side effects that are not indicated in the instructions appear, the patient should inform the doctor about it.

Application during pregnancy and lactation

The use of NovobismolЃ is contraindicated in pregnancy. During treatment with the drug, breastfeeding should be discontinued.

Application for impaired renal function

The use of the drug is contraindicated in case of severe renal dysfunction.

Application in children

The use of the drug is contraindicated in children under 4 years of age.

special instructions

Precautions for use The drug should not be used for more than 8 weeks. It is also not recommended to exceed the established daily doses for adults and children during treatment with NovobismolЃ. During the treatment period, you should not use other preparations containing bismuth. At the end of the course of treatment with the drug in recommended doses, the concentration of the active active substance in the blood plasma does not exceed 3-5.8 ?g / l, and intoxication is observed only at a concentration above 100 ?g / l. When using NovobismolЃ, stool may turn dark due to the formation of bismuth sulfide. Sometimes there is a slight darkening of the tongue. When destroying unused packages of the drug, special precautions are not required.Influence on the ability to drive vehicles and use mechanisms Does not affect the ability to drive a car and other mechanisms.Overdose

Symptoms: an overdose of the drug caused by prolonged use in doses exceeding the recommended ones can lead to impaired renal function. These symptoms are completely reversible when NovobismolЃ is discontinued.

Treatment: when signs of drug poisoning appear, it is necessary to wash the stomach, apply activated charcoal and saline laxatives. In the future, symptomatic treatment is carried out. In case of impaired renal function, accompanied by a high concentration of bismuth in the blood plasma, you can enter complexing agents - dimercaptosuccinic and dimercaptopropanesulfonic acids. In case of severe renal dysfunction, hemodialysis is indicated.

Drug interactions

Within half an hour before and after taking NovobismolЃ, it is not recommended to use other medicines inside, as well as to consume food and liquids, in particular, antacids, milk, fruits and fruit juices. This is due to the fact that, when taken simultaneously orally, they can affect the effectiveness of NovobismolЃ.